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a b s t r a c t
Background: Intra-abdominal adhesions are a major cause of morbidity after abdominal or
gynecologic surgery. However, knowledge about the pathogenic mechanism(s) is limited,
and there are no effective treatments. Here, we investigated a mouse model of bowel
adhesion formation and the effect(s) of an Federal Drug Administration-approved drug
(trametinib) in preventing adhesion formation.
Materials and methods: C57BL/6 mice were used to develop a consistent model of
intra-abdominal adhesion formation by gentle cecal abrasion with mortality rates of <10%.
Adhesion formation was analyzed histologically and immunochemically to
characterize the expression of pro-fibrotic marker proteins seen in pathologic scaring and
included alpha smooth muscle actin (aSMA) and fibronectin EDA (FNEDA) which arises from
alternative splicing of the fibronectin messenger RNA resulting in different protein iso-
forms. Trichrome staining assessed collagen deposition. Quantitative polymerase chain
reaction analysis of RNA isolated from adhesions by laser capture microscopy was carried
out to assess pro-fibrotic gene expression. To block adhesion formation, trametinib was
administered via a subcutaneous osmotic pump.
Results: Adhesions were seen as early as post-operative day 1 with extensive adhesions
being formed and vascularized by day 5. The expression of the FNEDA isoform occurred first
with subsequent expression of aSMA and collagen. The drug trametinib was chosen for
in vivo studies because it effectively blocked the mesothelial to mesenchymal transition of
rat mesothelium. Trametinib, at the highest dose used (3 mg/kg/d), prevented adhesion
formation while at lower doses, adhesions were usually limited, as evidenced by the
presence of FNEDA isoform but not aSMA.
* Corresponding author. Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, 233 South 10th Street,
Philadelphia, PA 19107. Tel.: þ1 (215) 573 5775; fax: þ1 (215) 503 5788.
E-mail address: Edward.Macarak@Jefferson.edu (E.J. Macarak).
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Conclusions: Cecal abrasion in mice is a reliable model to study abdominal adhesions, which
can be ameliorated using the MEK1/2 inhibitor trametinib. While blocking adhesion for-
mation at the cell and molecular levels, trametinib, at the therapeutic doses utilized, did
not impair the wound healing at the laparotomy site.
ª 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Although peritoneal adhesions may be caused by infection,
inflammation, or ischemia, surgical procedures are the pri-
mary cause since greater than 90% of patients will develop
adhesions after abdominal surgery.1 In the United States be-
tween 1998 and 2002, over 18% of hospital admissions were
secondary to abdominal adhesions alone resulting in
approximately 948,000 d of inpatient hospital care at an esti-
mated cost of 1.18 billion dollars.2 Such adhesions are
responsible for pelvic pain, bowel obstruction, and infertility.
Although modern advances in surgical technique, including
laparoscopy, have led to a decrease in their incidence, intes-
tinal adhesions still pose a very significant medical as well as
economic problem.3,4 Unfortunately, adequate therapeutic
solutions have proven elusive. While there are some studies
using therapeutics to attempt to prevent adhesion formation,
these have largely not gained wide acceptance.5-10 Similarly,
the use of barriers has also produced mixed results.11 Once
formed, adhesions are removed by adhesiolysis surgery. More
recent studies have shown that adhesiolysis procedures in the
United States account for 967,332 d of care at a cost of 2.3
billion dollars.12
Adhesion formation has a complex pathogenesis and can
be broken down into several stages which are as follows.
(1) An inflammatory response, whose blockage has largely
proven to be unsuccessful. It is characterized by an influx
of multiple cell types and production of a variety of cyto-
kines and factors.13,14
(2) The coagulation cascade and clot formation whose char-
acterization is critical to understand adhesion pathogen-
esis. Multiple studies provide a rational basis for
enhancing clot lysis as a therapeutic strategy. However, in
practice, this has proven difficult. These events occur early
postoperatively, and the failure of fibrinolysis allows
cellular infiltration of the initial fibrinous matrix.15-18
Although, in many cases, the formation of a clot is
essential to limit injury, resolution of the clot, in a timely
manner, is necessary to prevent adhesion formation.
Thus, the balance between fibrin clot formation and its
lysis is critical.
(3) The final stage in the adhesion process is formation of a
connective tissue scar. By and large, this stage causes the
most severe complications and has many common features
with fibrotic reactions foundelsewhere in the body, including
systemic ones (e.g., scleroderma) and those affecting indi-
vidual organs including lung, heart, liver, and kidney.
Because the pathophysiology of fibrotic reactions
has received insufficient attention, there exists an urgent
need for cellular and molecular characterization of adhesion
formation. The critical cell in the formation of an adhesion is
the myofibroblast which produces increased amounts of
fibrillar collagens as well as other matrix proteins and which
expresses alpha smooth muscle actin (aSMA), a molecular
marker of activated myofibroblasts.19,20 Although the origins
of myofibroblasts may differ depending on the affected organ
and the initiating event, in the abdominal cavity, they
may arise through a process of trans-differentiation of meso-
thelial cells in which these cells lose their specific epithelial
phenotypic markers such as expression of E-cadherin
and acquire a mesenchymal or myofibroblast phenotype.
This change in mesothelial phenotype has been termed
mesothelial-mesenchymal transition (MMT).
Since its first identification, it has been known that
transforming growth factor-b (TGF-b), a pleiotropic growth
factor with a wide and diverse spectrum of biological
activities, plays a key role in fibrotic diseases by mediating
the formation of myofibroblasts and stimulating the
production of extracellular matrix (ECM,21-24). In addition to
TGF-b, interleukin-6, another pleiotropic cytokine with a
diverse range of biological activities,25-27 was also found to
be elevated in peritoneal fluid during and/or after abdominal
surgeries thus potentially implicating it in the cascade of
events which lead to adhesion formation.28 Significantly, the
levels of these cytokines correlated with the severity of
abdominal adhesion formation.29,30 The complex signaling
pathways activated by TGF-b involve both canonical and
noncanonical signaling pathways. In the present context,
the critical downstream event elicited by noncanonical
signaling is the mitogen activated protein kinase (MEK)
activation of Erk1/2, which, when activated by phosphory-
lation, enters the nucleus and, in association with other
factors, mediate the transcription of pro-fibrotic genes and
cell cycle regulatory proteins (Fig. 1,31).
We have previously found that U0126, a MEK1/2
inhibitor not in clinical use, blocked the rat peritoneal
MMT induced by TGF-b.32 To extend these findings to a
drug with clinical potential, in the present study we have
evaluated the effect of the MEK1/2 inhibitor, trametinib,
currently in clinical use in the treatment of malignant
melanoma in humans, on the TGF-beinduced rat
peritoneal MMT and abdominal adhesion formation in a
mouse model. Trametinib effectively blocked the MMT
in vitro and markedly diminished adhesion formation
in vivo, likely by inhibiting the activation of Erk1/2.32
Taken together, these findings indicate that trametinib
may be a useful drug for the inhibition of adhesion
formation and warrant human clinical studies.
The goals of the present study were to use the mouse cecal
abrasion model to characterize the temporal pro-fibrotic
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cellular and molecular events that occur during adhesion
formation and determine whether the drug trametinib, a
MEK1/2 inhibitor, can block and/or alter these events.
Materials and methods
Reagents and antibodies
All reagents, unless otherwise specified, were purchased
from Sigma (St. Louis, MO). Polyvinylidene difluoride mem-
brane was purchased from Roche Diagnostics, Basel,
Switzerland. Antibodies to: Phospho-MEK1/2 (Ser217/221)
#9154, Phospho-Smad2 (Ser465/467) #3108, Phospho-Smad2
(Ser245/250/255) #3104, Phospho-p44/42 MAPK (Erk1/2)
(Thr202/Tyr204)#4370 were purchased from Cell Signaling
Technology, Danvers, MA. Antibody to the EDA isoform of rat
fibronectin (FNEDA) was developed and characterized by one
of us,33 and aSMA #ab5694 was purchased from Abcam,
Cambridge, MA. Trametinib was purchased from LC Labo-
ratories, Woburn, MA.
Isolation and culture of rat peritoneal mesothelial cells
The experiments in this study were approved by the Institu-
tional Animal Care and Use Committee at Thomas Jefferson
University and were performed in accordance with the
National Institutes of Health guidelines for the care and
Fig. 1 e TGF-b and interleukin-6 pathways leading to activation of MEK1/2 and Erk1/2 and their inhibition by trametinib.
Both TGF-b and interleukin-6 have been shown to activate a “downstream” common signaling pathway through Ras, which
results in the activation of Erk1/2. Erk1/2 has many potential downstream activities, but only their role(s) as transcriptions
factors is illustrated. Although the relevant pathways have been simplified for clarity, the figure shows the most important
elements in the present context. TGF-b [ transforming growth factor-b; LAP [ latency associated peptide, GP [
glycoprotein; SARA [ SMAD anchor for receptor activation; SMAD [ SMA and MAD related family of signal transducers;
CBP [ CREB binding protein; TF [ transcription factor; SHC [ SHC transforming protein, an adapter protein that couples
growth factor receptors to signaling pathways; GRB [ growth factor receptor bound protein. (Color version of figure is
available online.) This figure has been modified from two produced by ProteinLounge.
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handling of laboratory animals. Rat peritoneal mesothelial
cells (RPMCs) were isolated and cultured as described previ-
ously.34 Briefly, Sprague Dawley rats weighing 150g-250 g,
purchased from Jackson Laboratory, were injected intraperi-
toneally with 30 mL of 0.25% trypsin/2.21 mM EDTA under
isoflurane anesthesia andwere kept on themetal padwarmed
to 37C for 1 h after which the abdominal fluid was collected
and centrifuged at 300 g for 10 min. The pelleted cells
were resuspended and cultured in DMEM/F12 medium
(ThermoFisher Scientific, Philadelphia, PA) supplemented
with 10% (v/v) fetal bovine serum (ThermoFisher Scientific) at
37C in a humidified atmosphere of 5% CO2 in air. The RPMCs,
from the fourth to seventh passages (split ratio 1:4), at 90%
confluence were used for the experiments. The cells were
treated either with 10 ng/mL of TGF-b1 (R&D systems, Min-
neapolis, MN) alone or with TGF-b1 and the MEK1/2 inhibitor,
trametinib (2 or 5 nM).
Cecal abrasion model
Equal numbers of male and female C57BL/6 mice (18-25g,
8-10 wk of age, Jackson Laboratories, Bar Harbor, Maine) were
used in initial experiments while onlymale mice were used in
the drug escalation studies because they sustained greater
accumulations of fibrotic tissue (data not shown). Mice were
allowed to acclimate in the animal facility for at least 1 wk
before surgery, given free access to standard chow and water,
and a 12-h light-dark cycle in standard acrylic cages with
wood chip bedding. Animals were randomly assigned into
either an experimental group (laparotomy and cecal abrasion)
or a control group (laparotomy only).
Briefly, mice underwent induction and maintenance
anesthesia with 1%-3% isoflurane with supplemental oxy-
gen. After adequate sedation was achieved, mice were
weighed, and 0.1 mg/kg subcutaneous Buprenex (Hospira,
Inc, Lake Forest, IL) was administered to ensure analgesia.
The ventral surface was clipped along the midline, and the
skin was sterilized with betadine solution. A 2 cm midline
incision was made sub-xyphoid to avoid injuring the
bladder, and the cecum was identified and externalized. The
anti-mesenteric side of the cecum was gently swiped 30
times with gauze and then returned to the abdomen. We
found that 30 swipes were sufficient to promote the forma-
tion of petechial hemorrhagic regions and presumably inflict
damage to the mesothelial layer of the cecum. The incision
was closed with a double layer of sutures with 2-0 silk.35 To
characterize adhesion formation temporally, mice were
divided into groups, each with six males and six females
which were necropsied at 1, 2, 5, 8, 11, 14, 17, 21, and 23 d
post-surgery. Each time point also contained two male mice
and one female mouse as controls. In the drug escalation
study, laparotomy and cecal abrasion were carried out as
above as well as subdermal placement of the osmotic pumps
in the back of the mice.
Drug treatment with trametinib
Animals were treated with three different doses of the drug
trametinib dissolved in dimethyl sulfoxide (DMSO) in a dose
escalation study. Groups of five animals were given 0.1, 1.0, or
3.0 mg/kg animal weight of drug/d via osmotic pumps (Alzet
Osmotic Pump 1002, Cupertino, CA) for 8 d before sacrifice.
The volume delivered/d was 6 ml of drug. Control mice un-
derwent induction with anesthesia and laparotomy only. In
addition, five animals underwent laparotomy and placement
of the osmotic pumps which were filled with “drug vehicle”
(DMSO) alone, that is, no drug. After 8 d of drug or vehicle
treatment, mice were euthanized by CO2 asphyxiation fol-
lowed by cervical dislocation. The entire large intestine and
cecum were removed and partitioned for histology and
immunofluorescence microscopy. Adhesions were examined
by 2 independent practitioners.
Histology
Bowel and abdominal wall involved in the adhesion were
removed en bloc and fixed in 4% buffered formalin. Bowel
from nondrug-treated mice was also taken as a control.
Tissues were dehydrated, embedded in paraffin, and
sectioned at either 5 or 10 microns (m). Sections were
deparaffinized in a graded ethanol series and stained with
Masson’s trichrome stain. Three complete bowel segments (5
for 3-mg dosed mice) for each drug dose (0.1, 1.0, and 3.0 mg/
kg/d) were serially sectioned and all regions where bowel
segments were either close to one another or touching were
photographed using phase microscopy, and selected sec-
tions were then subsequently stained with trichrome and/or
processed for immunohistochemistry. Photographs were
taken with a Zeiss light microscope equipped with a Nikon
digital camera.
Table 1 e Primers employed for semi-quantitative real-time PCR
Gene Forward primer (50-30) Reverse primer (50-30)
18S ACCAGAGCGGAAAGCATTTGCCA TCGGCATCGTTTATGGTCGGAA
Col1a1 GCATGGCCAAGAAGACATCG TCCACGTCTCAGCATTGGG
Col3a1 AGCTTTGTGCAAAGTGGAACCTGG CAAGGTGGCTGCATCCCAATTCAT
Fn1 TCCAGGACAACAGCATCAGTGTCA CCACAGTGGGTTGCAAACCTTCAA
Fn-EDA TAAAGGACTGGCATTCACTGA GTGCAAGGCAACCACACTGAC
a-SMA GACTCTCTTCCAGCCATCTTTC GACAGGACGTTGTTAGCATAGA
Col1a1¼ collagen type 1 alpha chain; Col3a1¼ collagen type III alpha chain; Fn-EDA¼ fibronectin splicing isoform EDA; Fn1¼ plasma fibronectin;
a-Sma ¼ a-smooth muscle actin.
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Immunofluorescence microscopy
Bowel tissue was placed in Tissue-Tek O.C.T. Compound
(Sakura Finetek, Torrance, CA) and immediately frozen in
liquid nitrogen. Frozen sections were cut at either 5 or 10m,
allowed to adhere to albumin-coated slides and then washed
with phosphate buffered saline (PBS), followed by double
staining with goat anti-aSMA polyclonal antibody (1:100), and
anti-FnEDA antibody (1:75) after prior fixation in cold (4C
methanol) overnight at 4C. After washing 3X with PBS,
speciesematched Alexa-Fluor secondary antibodies (Invi-
trogen, Carlsbad, CA) were added and incubated for 1 h at
room temperature followed by three washes with PBS. Slides
were mounted with 4’,6-diamidino-2-phenylindole (DAPI)
Fluoromount-G (Southern Biotech, Birmingham, AL), and
fluorescence images were taken either with a Zeiss
epifluorescence microscope (5m sections) or a Nikon confocal
microscope (10m sections). Controls included: (1) omitting the
primary antibody and replacing it either with saline or indif-
ferent IgG from a control animal and (2) omission of the sec-
ondary antibody. In all instances, controls were either
negative or showed very slight nonspecific staining with the
secondary antibody alone (Fig. 7B).
RNA isolation and real-time PCR
Tissue from selected adhesions was isolated by laser cap-
ture microscopy affixed to membranes which were placed
in lysis buffer using a protocol provided by the instrument
manufacturer (Arcturus, ThermoFisher Scientific). Subse-
quently, RNA was isolated using the RNeasy Mini Kit (Qia-
gen, Valencia, CA). Isolated RNA was reverse transcribed
using All-in-One cDNA Synthesis SuperMix (Bimake,
Houston, TX) to generate first-strand complementary DNA.
Transcript levels of pro-fibrotic genes associated with
fibrosis and myofibroblast differentiation were determined
using SYBR Green real-time PCR as previously
described.36,37 Primers were designed using Primer Quest
(Integrated DNA Technologies, Skokie, Illinois) and were
validated for specificity. The sequences of the primers
employed are shown in Table 1. The differences in the
number of mRNA copies in each PCR were corrected for 18S
RNA endogenous control transcript levels; expression
levels in day 5 mice were set at 100%, and all other values
were expressed as normalized multiples of these values.
Western blotting analysis
RPMCs were lysed in ice-cold modified RIPA buffer with
protease inhibitor cocktail (50 mM/L Tris-HCl, 1% NP-40,
0.25% sodium deoxycholate, 150 mM/L NaCl, 1 mM/L EDTA,
1 mM/L phenylmethyl sulfonyl fluoride, 1 mM/L sodium
orthovanadate, 1 mM/L sodium fluoride, pH 7.4). Equivalent
Fig. 2 e (A) Cultured rat peritoneal mesothelial cells treated
either with TGF-b alone or plus trametinib. Cells treated
with TGF-b alone (upper right panel) show cells
transitioning to a fibroblast-like morphology while cells
treated with TGF-b D trametinib (5 nM) show no such
morphologic changes (lower right panel). (B) Western
analysis of proteins isolated from rat peritoneal
mesothelial cells treated with and without TGFb and with
and without trametinib. Note that p-Erk1/2 shows a
dramatic reduction after stimulation with TGFb1 in the
presence of either 2 or 5 nM trametinib as do FNEDA, aSMA,
and the p-Smad2 (linker region). TGF-b [ transforming
growth factor-b; fSMA [ alpha smooth muscle actin;
FNEDA [ fibronectin EDA; GAPDH [ glyceraldehyde 3-
phosphate dehydrogenase. (Color version of figure is
available online.)
Fig. 3 e Trichrome-section through adjacent intestinal
loops showing a forming adhesion on day 1 post-surgery.
The forming adhesion consists of a loose granular tissue
with little organized structure. (Color version of figure is
available online.)
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amounts of homogenate (50 mg/well), determined by Coo-
massie blue assay, were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis, transferred to either
nitrocellulose or polyvinylidene difluoride membranes, and
detected by either SuperSignal West Femto or SuperSignal
West Pico chemiluminescence substrate (ThermoFisher
Scientific).
Results
Effect of trametinib on mesothelial/mesenchymal transition
Isolated mesothelial cells were incubated under control con-
ditions without either TGF-b or trametinib, with TGF-b or
trametinib alone, or with both TGF-b and trametinib for 5 d
(Fig. 2A). We have previously found that this length of time
was required for maximal mesothelial/mesenchymal transi-
tional effect of TGF-b on these rat cells.32 As before, TGF-b
produced a dramatic transitional effect (upper right panel),
markedly altering the appearance of the cells from their
normal morphology (upper left panel), whereas trametinib
alone had no effect and no apparent toxic effectswith the cells
maintaining a cobblestone appearance (lower left panel).
Remarkably, trametinib blocked the effect of TGF-b, and the
cells retained their epithelial morphology (lower right panel).
Based on our early observations (data not shown), TGF-
betreated cells gained aSMA and COL1A1 expression, which
was prevented by treatment with 5 nM trametinib. These in-
sights led us to explore the potential mechanisms of action of
trametinib using Western blotting analyses (Fig. 2B). These
experiments demonstrated that TGF-b produced a substantial
increase in the phosphorylation/activation of Erk1/2 and
phosphorylation of the Smad2 linker region38 as well as
increases in expression of aSMA and FNEDA. These increases
in the expression of p-Erk1/2, FNEDA, aSMA, and p-SMAD2
(linker) were blocked by as low a concentration of trametinib
as 2 nM (Fig. 2B).
Fig. 4 e Trichrome-stained section through adjacent
intestinal loops showing a forming adhesion on day 2
post-surgery. The forming adhesion is becoming more
cellular, vascular, and substantial. (Color version of figure
is available online.)
Fig. 5 e Section through adjacent intestinal loops stained with an antibody to FNEDA showing a forming adhesion at day
2 post-surgery. (A) Combined phase-immunofluorescence photograph showing the localization of the FNEDA antibody
(arrows) within the forming adhesion (3100). (B) Photograph of the same area as (A) but taken at a higher magnification
(3400). FNEDA [ fibronectin EDA. (Color version of figure is available online.)
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Characterization of adhesion formation in the mouse model
To characterize adhesion formation in themousemodel, mice
sacrificed at post-surgery time points after cecal abrasion
were examined by both trichrome staining and immunohis-
tochemistry using antibodies raised against pro-fibrotic pro-
teins. The histology of the large intestine of the mouse is
similar to that of humans and consists of a lining of columnar
epithelium containing many goblet cells. The epithelium
surrounding the lumen is underlain by a somewhat poorly
characterized myofibroblast layer embedded in the lamina
propria and surrounded by a submucosa and two layers of
muscularis (an inner circular and an outer longitudinal layer)
covered with a thin layer of mesothelium.
The first appearance of adhesions was seen as early as day
1 with the appearance of loose granulation tissue between
adjacent intestinal loops and/or the cecum (Fig. 3). The
development of the adhesion proceeds during day 2 with
increasing cellularity and vascularity within the developing
adhesion (Fig. 4). In addition, there is the appearance of FNEDA
on day 2, which first is deposited in the small space between
the closely apposed bowel loops (Fig. 5A). Figure 5B is an
immunofluorescent image from the same region as shown in
Figure 5A but at a greater magnification; it clearly shows that
FnEDA is initially deposited as the adhesion is in its formative
stage in the region between the adjacent intestinal loops.
Between day 2 and day 5 after surgery, the adhesion develops
rapidly with greater cellularity as well as vascularization of
the newly generated adhesion as shown in Figure 6. The
adhesion is a well-formed entity with many blood vessels
including arterioles and venules and the presence of a
collagen-containing ECM (blue trichrome staining, arrow).
Thus, the day 5 adhesions appear robust with well-formed
blood vessels in an organized matrix containing type I
collagen and FnEDA. Initially, type III collagen is also present
(data not shown). Interestingly, at day 5 post-surgery, cells
that localize antibody to aSMA are present as shown in
Figure 7. In the same figure, the antibody to aSMA also local-
ized extensively to smoothmuscle of multiple small and large
blood vessels whose staining serve as an internal control for
antibody specificity. The small inset in Figure 6 is a control
stained with DAPI but without antibody to aSMA. Adhesions
that are present at day 8-23 post-surgery illustrate a continued
maturation of the adhesions, which become highly cellular
and vascular. By day 20, the adhesion is robust and highly
cellular with many well-developed blood vessels (Fig. 8).
To quantify the progressive connective tissue changes in
adhesions temporally, measurements of pixel density were
carried using a Nikon A1R confocal microscope. Images of
tissues stained with antibody to type I collagen were collected
from three different mouse samples for each time point.
Multiple adhesions from each of three 5 day and three 8-day
post-surgery adhesions were analyzed using Image J image
analysis of confocal photographs. For photographs used for
the quantification of collagen, the camera settings were un-
changed for all photographs taken with the digital camera. As
shown in Table 2, there is a highly statistically significant in-
crease (P ¼ 1.6  104) in the level of type I collagen found in
adhesions at 8 d postsurgery versus those at 5 d.
To determine if differences in gene expression were associ-
ated with the histologic and immunohistochemical changes
observed, laser capture dissection of the adhesive tissue was
Fig. 6 e Trichrome-stained section through adjacent
intestinal loops showing a forming adhesion on day 5
post-surgery. Highly cellular and well-formed adhesion
with both arterial and venous structures. Note the central
blue staining region (arrow) within the adhesion indicating
the presence of collagen. (Color version of figure is
available online.)
Fig. 7 e Confocal immunofluorescent photograph showing
localization of antibody to aSMA within a forming
adhesion on day 5 post-surgery. (aSMA [ red, DAPI
nuclear stain[ blue). (A) Note the abundant localization of
antibody to aSMA to cells within the adhesion indicating
the presence of myofibroblasts within the adhesion. There
is also localization of the antibody to the smooth muscle
cells associated with the tunica media of blood vessels
within the same area which serves as a “positive” control
for the antibody (arrows). 3100. (B) Control photograph of
region between two intestinal loops showing adhesion
area (bracket) incubated with two secondary antibodies
alone (no primaries) and DAPI nuclear stain showing no
specific localization. Bracket indicates region of adhesion.
3100. aSMA[ alpha smooth muscle actin. Arrows point to
artery on left, small arterioles in center and large vein on
right. (Color version of figure is available online.)
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carried out. Adhesions were identified and boundaries of the
adhesions defined by the staining of the muscularis externa
with phalloidin (Fig. 9). Tissue between adjacent bowel loops
was captured and subjected to RNA isolation and quantitative
polymerase chain reaction (qPCR) quantification as described in
theMethods.Thesedata,whichareshown inFigure9andwhich
showanapproximately four fold increase in type I collagen gene
expression, corroborate measurements of type I collagen pixel
density (Table 2). Thus, immunohistochemistry and qPCR both
show increased expression of type I collagen between day 5 and
day 8. In addition, qPCR measurements also showed increased
expression for type III collagen (wseven fold increase), plasma
Fn (w5- fold increase), aSMA (wfive fold increase), and FnEDA
(w10-fold increase). Interestingly, of the pro-fibrotic genes
measured, the largest overall increasewas thatof FnEDA (Fig. 10).
Trametinib drug treatment
To evaluate the effect(s) of the drug trametinib on adhesion
formation, a series of experiments were carried out in which
mice were treated with three different concentrations of
trametinib over an 8-day period. Animals appeared to tolerate
the drug with no adverse events noted (changes in behavior,
eating, weight loss). Changes in average weight within each
dosage group over the 8 d period of drug delivery were unre-
markable: 1.0 mg dose - 2.2 % average decrease in weight,
3.0 mg dose: 0.5% average increase in weight. As well, there
appears to be no effect on wound closure and healing (Fig. 11).
The surgical site shown is representative of the animals
receiving the highest drug dose (3 mg/kg/d). In most of the
animals, the wound was essentially healed by 8 d post-sur-
gery. Since the drug is minimally soluble in water, DMSO was
used as a “vehicle” to solubilize it. To investigate the possi-
bility that the DMSO itself may induce side effects, an addi-
tional series of five animals were subjected to the same
surgeries as themice receiving drug, that is, laparotomies and
sub-dermal osmotic pump placement; however, for these
additional animals, the pumps contained DMSO but no drug.
Analysis of these animals demonstrated that the DMSO
neither had any effect on survivability nor wound healing.
Thus, although these animals developed abdominal adhe-
sions, they showed no discernible consequences of the treat-
ment with DMSO (data not shown).
In Figure 12A, the adhesion between adjacent bowel
loops of a day 8 post-surgery mouse treated with trametinib
(0.1 mg/kg/d) show cells largely localizing antibody to FnEDA in
the center of the adhesion. There does not appear to be any
cells which localize antibody to aSMA. In Figure 12B, the
adhesion, also treatedwith 0.1mg/kg/d of trametinib, appears
to be a more advanced adhesion than that shown in
Figure 12A since there are more myofibroblast cells localizing
antibody to aSMA. Nevertheless, few cells (arrows) localize
antibody to aSMA suggesting the presence of a modest
Fig. 8 e Trichrome-stained section through adjacent
intestinal loops showing a mature adhesion on day 20
post-surgery. This region illustrates a well-formed mature
adhesion with a highly vascularized structure within a
collagenous extracellular matrix. The adhesion has an
abundance of cells, many of which are likely
myofibroblasts based upon their localization of antibody
to aSMA at day 5 as shown above in Fig. 7B. 3100. aSMA
[ alpha smooth muscle actin. (Color version of figure is
available online.)
Table 2 e Mean gray values of adhesions at day 5 and 8
postsurgery.
Time point Mean gray value Standard deviation
Day 5 658.10 277.67
Day 8 1008.30 461.49
% Increase: 53
Student t-test P ¼ 1.6  104
Fig. 9 e Laser capture image of tissue selected for qPCR.
Representative tissue sections from 5 to 8 d pro-fibrotic
mice were cut at 15 microns and adhered to Arcturus
microslides. Adhesion areas were identified after prior
staining of the sections with phalloidin. These areas were
marked for laser dissection and collected according to the
Arcturus protocols in Qiagen RLT lysis buffer for
subsequent RNA extraction. (Color version of figure is
available online.)
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number of myofibroblasts. This adhesion is much less well-
developed than that shown in Figure 5 despite the presence of
vascular structures present (arrows) and a weakly developed
ECM. The abraded cecum reacts to the physical damage by
producing FnEDA.
Figure 13 shows closely adjacent intestinal loops from
different animals treated with 3 mg/kg/d of trametinib. The
space between the loops is clearly defined but shows no sign of
a developed adhesion (bracket). The examples shown in this
figure are typical of all the bowel sections taken from animals
receiving the highest drug dose. Although there were regions
where intestinal loops were close to one another, as shown in
Figure 13, no adhesions were observed in these regions.
Discussion
We have used a mouse model of cecal abrasion to initiate the
formation of abdominal adhesions. Adhesion formation be-
gins almost immediately after surgery and adhesion sites
show evidence of the presence ofmyofibroblasts within 5 d, as
demonstrated by cells expressing aSMA and FnEDA within the
developing adhesion. We did not address the origin of the
myofibroblasts because it is beyond the scope of this study;
however, our in vitro experiments with RPMCs suggest the
possible contribution of mesothelial cells to the pathophysi-
ology of adhesion formation.
Myofibroblasts, associated with fibrotic reactions, may
arise from different sources depending on the affected organ
and the initiating event including: (1) activation of tissue
resident fibroblasts in response to specific signals from
infiltrating inflammatory cells36; (2) recruitment of bone
marrow precursor cells known as fibrocytes which express
bone marrow cellular surface markers such as CD34 but are
capable of ECM production36,37; and (3) trans-differentiation of
epithelial, mesothelial, and endothelial cells into activated
myofibroblasts. Although this process was originally
described in epithelial cells and designated epithelial to
mesenchymal transition, it is now known that very similar
processes occur in the case of mesothelial (MMT) and endo-
thelial (EndoMT) cells.41-43
In these transitions, the epithelial, mesothelial, or endo-
thelial cells lose their cell typedspecific markers and pheno-
typic traits, such as expression of E-cadherin and acquire a
mesenchymal or myofibroblast phenotype, ultimately initi-
ating the expression of aSMA and vimentin and ECM proteins
including FnEDA. The expression of these proteins is consistent
with a transition of the mesothelial cells to myofibroblasts.43,44
Similarly, our immunofluorescence data in themousemodel at
2 d post-surgery show the presence of FnEDA within the adhe-
sions suggesting that these FnEDA positive cells either have or
are transitioning into a contractile myofibroblast.
Cells which are FnEDA “positive” and aSMA “negative” are
considered proto-myofibroblasts, and it is only later after the
proto-myofibroblasts express aSMA that they are termed myo-
fibroblasts. Thus, the presence of contractile myofibroblasts is
a hallmark of fibrotic tissue whose maturation is preceded by
the expression of FnEDA.20 The fact that some cells within the
adhesion, shown in Figure 11A, express only FnEDA and not
aSMA (compare Fig. 12A and B) suggests that trametinib may
interfere with the conversion of the precursor proto-myofibro-
blast into a myofibroblast. A functional consequence of this
may be the inability of the proto-myofibroblast to contract since
Fig. 10 e qPCR of laser-captured tissue from 5 to 8 d
adhesions. Transcript levels of pro-fibrotic genes were
quantified using SYBR Green real-time PCR.39,40 Primers
were designed using Primer Quest (Integrated DNA
Technologies) and were validated for specificity (Table 1).
The differences in the number of mRNA copies in each PCR
were normalized for 18S RNA endogenous control
transcript levels. In the figure, expression levels in control
mice were set at 100%, and all other values were expressed
as normalized multiples of these values. Day 5 values were
set to 1. Col1a1 [ collagen type 1 alpha chain;
Col3a1 [ collagen type III alpha chain; Fn-
Eda [ fibronectin splicing isoform EDA; Fn1 [ plasma
fibronectin; and a-Sma [ a-smooth muscle actin. All data
were reported as the mean (± standard error of the mean)
of at least three separate animals. Statistical analysis was
performed using a t-test, and the level of significance was
set at P< 0.05 or less.
Fig. 11 e Photographof theabdomenofamousetreatedwith
the highest dose of trametinib. The laparotomy site (dotted
line) has almost completely healed by 8 d post-surgery. In
some animals, therewas complete closure of the incision by
8 d. (Color version of figure is available online.)
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both aSMA and FnEDA are required to mediate the transfer of
intracellular force to the ECM.44 It has been demonstrated that
myofibroblast contraction activates latent TGF-b1 releasing it
from the ECM, which initiates the pro-fibrotic cascade of
events.45,46
Figures 7A and 12B show adhesions in control mice and
those dosed with 0.1 mg/kg/d of trametinib and clearly show
an abundance of aSMA-positive cells. Presumably, these are
the cells producing the collagen that accumulates within the
adhesion as demonstrated not only by histologic and immu-
nohistochemical methods but also by pixel intensity quanti-
fication of confocal images and qPCR (Table 2 and Fig. 10). It is
important to note that the occurrence of adhesions in the
drug-treated animals given the highest dose of trametinib
(3 mg/kg/d) must be an extremely rare event if it occurs at all.
In the five animals whose bowels were serially sectioned,
we observed regions where the cecum and intestinal
loops were in close proximity to one another but without
development of a discernible adhesion (Fig. 14). When such
regions were found in the trametinib-treated animals (0.1 and
1.0 mg/kg/d dose levels), lesion development appeared to be
inversely proportional to the level of drug administered. For
example, fairly extensive lesions were found at the lowest
dose while mice administered the 1 mg/kg/d had adhesions
which were poorly formed and which appeared to have low
levels of aSMA “positive” cells. These data support the view
that adhesions in mice treated with the middle dose of tra-
metinib (1 mg/kg/d) had limited complete trans-differentiation
of cells into myofibroblasts, which we and others define as a
cell expressing both aSMA and FNEDA.20,47,48 This diminution
of myofibroblast presence is in contrast to that found either in
untreated animals or in animals receiving the lowest dose
(Fig. 12B). This suggests that trametinib may be active in
ameliorating and/or blocking the early stages of adhesion
formation, something which may be useful in preventing
formation in humans.
The localization of FNEDA (Figs. 5 and 12A) occurred in the
central region either between the cecum and bowel loops or
associated with the surface of the abraded cecum. These
central regions quickly became highly cellular and vascu-
larized. Our in vitro studies with rat mesothelial cells show
that after stimulation with TGF-b, they undergo MMT and
begin expressing both aSMA and FnEDA and that U0126, a
Mek1/2 inhibitor, was very effective in blocking their MMT.32
Practically, mesothelial cells are reasonable candidates to
trans-differentiate into myofibroblasts as others have sug-
gested.49,50 However, much additional work will need to be
carried out to validate this possibility because it is also
Fig. 12 e Immunofluorescence confocal photographs of two adhesions at day 8 post-surgery from mice treated with
0.1 mg/kg/d of trametinib (FnEDA[ green, aSMA[ red, DAPI nuclear stain[ blue, M[muscularis). (A) Antibody to FNEDA
is prominently localized to the adhesion center while only a few cells localize antibody to aSMA 3200. (B) Extensive
localization of antibody to aSMA to the smooth muscle cells of the muscularis externa is shown. In addition, note the
localization of aSMA to many myofibroblasts and blood vessels within the adhesions. 3200. aSMA [ alpha smooth
muscle actin; FNEDA [ fibronectin EDA. (Color version of figure is available online.)
Fig. 13 e Immunofluorescence confocal photograph of a
section through adjacent intestinal loops showing a
potential adhesion (bracket) in mice treated with 0.1 mg/
kg/d of trametinib on day 8 post-surgery (FnEDA [ green,
aSMA [ red, DAPI nuclear stain [ blue). Note that the
region between the cecum and the bowel segment (a
presumptive adhesion, bracket) is devoid of cells localizing
antibody neither to FnEDA nor aSMA and that only the
cecum is expressing FnEDA as a result of the abrasion
technique. The opposite bowel loop has intact mesothelial
nuclei and likely represents uninvolved bowel. 3200.
aSMA [ alpha smooth muscle actin; FNEDA [ fibronectin
EDA. (Color version of figure is available online.)
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possible that the myofibroblasts may originate from other
sources as well.51-53 Interestingly, qPCR data of RNA isolated
from adhesions by laser capture microscopy at day 5 and
8 postsurgery show the expression of FnEDA, aSMA, and
collagen increased significantly raising the possibility that
MMT may occur in vivo.
In our current investigation, these previous in vitro studies
using UO1126 were duplicated using trametinib on RPMCs
with similar results to those found at both the morphologic
and molecular levels. In the presence of trametinib, the
characteristic cobblestone appearance of normal mesothelial
cells was maintained (Fig. 2), the expression of FnEDA and
aSMA was inhibited, and the phosphorylation of Erk1/2 was
essentially blocked completely (Fig. 2B). Interestingly, the
concentrations of trametinib used in the present experiments
were considerably lower (2 or 5 nM) than that used in exper-
iments involving cultured melanoma cells (100 nM,54). This
suggests that a positive therapeutic response with trametinib
could be attained at a much lower dose in fibrotic reactions
than that required for tumor responses in vivo, minimizing
any potential toxic events of the drug.
Significantly, during adhesion formation in the mouse
model, there was a rapid formation of blood vessels within
the adhesion. Since surgery may disrupt blood flow, a conse-
quence is that the tissue becomes hypoxic which is acceler-
ated by the rapid influx of highlymetabolic inflammatory cells
participating in the wound healing process. These cells
initiate the formation of granulation tissue and promote the
trans-differentiations and proliferation of the myofibroblasts.
For example, fibroblasts can be induced to secrete increased
amounts of TGF-b under hypoxic conditions thus contributing
to the overall pro-fibrotic process duringwound healing.55 The
role of hypoxia has been further corroborated by studies in
rats which demonstrated that hyperbaric oxygen can reduce
the pro-fibrotic changes associated with intra-abdominal ad-
hesions56 presumably by increasing PO2 tissue levels.
The present findings demonstrate that trametinib can
effectively inhibit adhesion formation in a mouse model that
Fig. 14 e Group of trichrome-stained sections through adjacent intestinal loops on day 8 post-surgery mice treated with
3 mg/kg/d of trametinib. Mice treated with the highest dose of trametinib (3.0 mg/kg/d) essentially developed no adhesions.
Although there are many potential adhesion regions where the intestinal loops with intact epitheliummuscularis layers are
close together, (as shown here), none of these areas developed adhesions (evidenced by the lack of granulation tissue)
similar to those observed either in control animals or animals which received lower doses of trametinib. (Color version of
figure is available online.)
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mimics potential human clinical situations. Since previous
treatments have met with limited success, new therapeutic
approaches are necessary and additional clinical testing of
trametinib will be required to validate its use in humans. Most
importantly with respect to its therapeutic use in humans, our
observations also demonstrate that the effective dosage(s) of
trametinib used had no adverse effect on the healing of the
surgical wound required to access the abdominal cavity in the
mouse model. At necropsy 8 d post-surgery both the abdom-
inal musculature and the overlying skin had largely healed.
This demonstrates that trametinib, at least in the mouse
model, did not impede wound healing.
In summary, these data suggest that abdominal adhesion
formation appears to be the result of common patho-
physiologic mechanisms operative in other fibrotic reactions
mediated, at least in part, by the phosphorylation of Erk1/2.
Activation of these signaling pathways results in formation of
an ECM containing collagen57 and FNEDA in resident cells.58
Conclusions
1. Cecal abrasion is a reliable model for generation of intra-
abdominal adhesions.
2. Trametinib, a MEK1/2 inhibitor, ameliorated adhesion for-
mation with little or no effect on wound healing at the
laparotomy site in mice.
3. Adhesions quickly become populated by myofibroblasts as
the adhesions matured which did not occur in mice treated
with 3 mg/kg/d of trametinib.
4. This model may be of great use to test the effects of other
therapeutic agents on abdominal adhesion formation.
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